Atomoxetine
- PDF / 170,183 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 8 Downloads / 188 Views
1
Atomoxetine Raynaud’s Phenomenon: case report A 7-year-old boy developed Raynaud’s Phenomenon while receiving atomoxetine for autism spectrum disorder (ASD) and attention deficit/hyperactivity disorder (ADHD). The boy was diagnosed with ASD and ADHD. Subsequently, he started receiving atomoxetine 10 mg/day as 0.5mg/(kg.d) dose basis at morning [route not stated]. After 1 week, the dose was increased to 18 mg/day. No significant side effects were reported. Hence, 2 weeks later, the dose of atomoxetine was titrated to 28 mg/day. Two days after initiation of atomoxetine 28 mg/day, the mother reported that he had bilateral digital pallor and cooling, and circumoral cyanosis which had developed following 1 hour of the first dose of atomoxetine 28 mg/day and lasted for 2 days. He was suspected with Raynaud’s Phenomenon and consultation with paediatric rheumatologist was made. Examination of upper limbs revealed bilateral peripheral pallor while the rest of the physical examination was normal. The use of any drug, herbal product, or substance was denied by his mother. There was no consanguinity between parents and no family history of rheumatologic disease. There was no history of cyanosis on hands related to cold exposure, arthralgia, arthritis, xerophthalmia, xerostomia and photosensitivity. Other investigation were unremarkable. No underlying pathology was identified. Diagnosis of Raynaud’s made. The boy’s treatment with atomoxetine was discontinued and his symptoms resolved. Author comment: "Similar to the previous report, in our case, [Raynaud’s Phenomenon] emerged immediately after [atomoxetine] was increased to 28 mg/day and the symptoms had improved after discontinuation of [atomoxetine].""Assessment with Naranjo Adverse Drug Reaction Probability Scale revealed a score of 8 that shows probable adverse drug reaction." Gulle ZN, et al. Raynaud's Phenomenon Related with Atomoxetine Treatment in a Child with Autism and Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology 29: 649-650, No. 8, Oct 2019. Available from: URL: http://doi.org/10.1089/cap.2019.0025 803435453 Turkey
0114-9954/19/1780-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 23 Nov 2019 No. 1780
Data Loading...
